Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03684018 · ClinicalTrials.gov registry record · Phase 4
Two Dose Levels of Privigen in Pediatric CIDP
A Phase 4 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by CSL Behring.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT03684018 is a Phase 4 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) that is actively recruiting participants, run by CSL Behring. The registered enrollment target is 30 participants. The trial reports 9 study locations across 9 states.
The verdict
NCT03684018, a Phase 4 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), is actively recruiting participants, sponsored by CSL Behring.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Conditions Studied
Interventions
- BIOLOGICAL IgPro10
Study Locations (9)
Arizona
- Phoenix Children's Hospital - Phoenix
California
- Children's Hospital of Los Angeles - Los Angeles
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Ohio
- Akron Children's Hospital - Akron
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Le Bonheur Children's Hospital - Memphis
Texas
- Neurology Rare Disease Center - Denton
Virginia
- Children's Specialty Group - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-02-28 |
| Est. Completion | 2029-12-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03684018
The ClinicalTrials.gov registry entry for NCT03684018 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) appearing as the primary indexed condition, and to 1 intervention - of which IgPro10 is the first listed.
NCT03684018 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arizona, California, Iowa.
Frequently Asked Questions
What is clinical trial NCT03684018 about?
NCT03684018 is a clinical study titled "Two Dose Levels of Privigen in Pediatric CIDP". A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
What is the current status of trial NCT03684018?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2019-02-28. Estimated completion is 2029-12-20.
What conditions does trial NCT03684018 study?
This clinical trial studies the following conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
What interventions are being tested in trial NCT03684018?
The interventions under investigation include: IgPro10 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03684018?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03684018 being conducted?
This trial has 9 study locations across Arizona, California, Iowa, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.